Drug
NE3107
NE3107 is a pharmaceutical drug with 6 clinical trials. Currently 2 active trials ongoing. Historical success rate of 75.0%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
2(33%)
Results Posted
33%(1 trials)
Terminated
1(17%)
Phase Distribution
Ph phase_3
1
17%
Ph phase_1
1
17%
Ph phase_2
4
67%
Phase Distribution
1
Early Stage
4
Mid Stage
1
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
4(66.7%)
Phase 3Large-scale testing
1(16.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
6
all time
Status Distribution
Active(2)
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Recruiting1
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
2
Success Rate
75.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (16.7%)
Phase 24 (66.7%)
Phase 31 (16.7%)
Trials by Status
terminated117%
recruiting117%
active_not_recruiting117%
completed350%
Recent Activity
2 active trials
Showing 5 of 6
active_not_recruitingphase_2
A Study of NE3107 in Early Parkinson's
NCT06757010
recruitingphase_2
NE3107 in Adults With Neurological Symptoms of Long COVID
NCT06847191
terminatedphase_2
Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury
NCT05970575
completedphase_2
Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia
NCT05227820
completedphase_3
A Phase 3 Study of NE3107 in Probable Alzheimer's Disease
NCT04669028
Clinical Trials (6)
Showing 6 of 6 trials
NCT06757010Phase 2
A Study of NE3107 in Early Parkinson's
NCT06847191Phase 2
NE3107 in Adults With Neurological Symptoms of Long COVID
NCT05970575Phase 2
Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury
NCT05227820Phase 2
Insulin-Sensitizing Anti-Inflammatory Small Molecule for Investigative Treatment of Dementia
NCT04669028Phase 3
A Phase 3 Study of NE3107 in Probable Alzheimer's Disease
NCT05083260Phase 1
NE3107 Activity and Safety in Patients With Parkinson's Disease Using Levodopa
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6